<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "9: product research", fill: "#f88379"},
{source: "9: product research", target: "9: development program significant", fill: "#f88379"},
{source: "9: development program significant", target: "9: expenditures", fill: "#f88379"},
{source: "9: expenditures", target: "9: losses will continue until development", fill: "#f88379"},
{source: "9: losses will continue until development", target: "9: new products", fill: "#f88379"},
{source: "9: new products", target: "9: such products", fill: "#f88379"},
{source: "9: such products", target: "9: been clinically tested approved by", fill: "#f88379"},
{source: "9: been clinically tested approved by", target: "9: regulatory agencies", fill: "#f88379"},
{source: "9: regulatory agencies", target: "9: successfully marketed", fill: "#f88379"},
{source: "9: product research", target: "10: operations primarily through", fill: "#555"},
{source: "10: operations primarily through", target: "10: equity securities", fill: "#555"},
{source: "10: equity securities", target: "10: product development", fill: "#555"},
{source: "10: product development", target: "10: activities", fill: "#555"},
{source: "10: operations primarily through", target: "13: new generation", fill: "#f984ef"},
{source: "13: new generation", target: "13: therapeutic", fill: "#f984ef"},
{source: "13: therapeutic", target: "13: drug products but such products cannot", fill: "#f984ef"},
{source: "13: drug products but such products cannot", target: "13: marketed until", fill: "#f984ef"},
{source: "13: marketed until", target: "13: clinical testing", fill: "#f984ef"},
{source: "13: clinical testing", target: "13: governmental approvals", fill: "#f984ef"},
{source: "13: new generation", target: "17: additional", fill: "#673147"},
{source: "17: additional", target: "17: development", fill: "#673147"},
{source: "17: development", target: "17: activities", fill: "#673147"},
{source: "17: additional", target: "18: raised equity financing", fill: "#c2b280"},
{source: "18: raised equity financing", target: "18: such financing on", fill: "#c2b280"},
{source: "18: such financing on", target: "18: requirements", fill: "#c2b280"},
{source: "18: raised equity financing", target: "26: possibility", fill: "#e08d3c"},
{source: "26: possibility", target: "26: drug candidate will", fill: "#e08d3c"},
{source: "26: drug candidate will", target: "26: ineffective", fill: "#e08d3c"},
{source: "26: ineffective", target: "26: unacceptably toxic ii", fill: "#e08d3c"},
{source: "26: unacceptably toxic ii", target: "26: necessary regulatory clearances iv", fill: "#e08d3c"},
{source: "26: necessary regulatory clearances iv", target: "26: broad market acceptance v", fill: "#e08d3c"},
{source: "26: broad market acceptance v", target: "26: competition from third parties", fill: "#e08d3c"},
{source: "26: competition from third parties", target: "26: may market equivalent", fill: "#e08d3c"},
{source: "26: may market equivalent", target: "26: products vi", fill: "#e08d3c"},
{source: "26: products vi", target: "26: affected by third", fill: "#e08d3c"},
{source: "26: affected by third", target: "26: proprietary rights", fill: "#e08d3c"},
{source: "26: proprietary rights", target: "26: will preclude us from marketing", fill: "#e08d3c"},
{source: "26: will preclude us from marketing", target: "26: drug product", fill: "#e08d3c"},
{source: "26: drug product", target: "26: manufactured by manufacturers", fill: "#e08d3c"},
{source: "26: manufactured by manufacturers", target: "26: timely manner", fill: "#e08d3c"},
{source: "26: timely manner", target: "26: accordance with", fill: "#e08d3c"},
{source: "26: possibility", target: "30: commercializing", fill: "#8f00ff"},
{source: "30: commercializing", target: "30: candidates", fill: "#8f00ff"},
{source: "30: candidates", target: "30: investment", fill: "#8f00ff"},
{source: "30: commercializing", target: "33: clinical trials", fill: "#39ff14"},
{source: "33: clinical trials", target: "33: future clinical trials will", fill: "#39ff14"},
{source: "33: future clinical trials will", target: "33: drug candidates will", fill: "#39ff14"},
{source: "33: drug candidates will", target: "33: necessary regulatory approvals", fill: "#39ff14"},
{source: "33: necessary regulatory approvals", target: "33: marketing distribution", fill: "#39ff14"},
{source: "33: marketing distribution", target: "33: such drug candidates", fill: "#39ff14"},
{source: "33: clinical trials", target: "39: will face intense competition from", fill: "#a3c1ad"},
{source: "39: will face intense competition from", target: "39: pharmaceutical", fill: "#a3c1ad"},
{source: "39: will face intense competition from", target: "45: cannot assure", fill: "#e3256b"},
{source: "45: cannot assure", target: "45: existing products", fill: "#e3256b"},
{source: "45: existing products", target: "45: new products", fill: "#e3256b"},
{source: "45: new products", target: "45: by competitors will", fill: "#e3256b"},
{source: "45: by competitors will", target: "45: effective", fill: "#e3256b"},
{source: "45: effective", target: "45: effectively marketed", fill: "#e3256b"},
{source: "45: cannot assure", target: "69: marketability", fill: "#fbab60"},
{source: "69: marketability", target: "117: senior executive officers", fill: "#9f00ff"},
{source: "117: senior executive officers", target: "117: chief executive officer", fill: "#9f00ff"},
{source: "117: chief executive officer", target: "117: chief financial officer", fill: "#9f00ff"},
{source: "117: chief financial officer", target: "117: particular could", fill: "#9f00ff"},
{source: "117: particular could", target: "117: common stock particularly", fill: "#9f00ff"},
{source: "117: senior executive officers", target: "146: common stock", fill: "#004040"},
{source: "146: common stock", target: "146: biomedical technology companies", fill: "#004040"},
{source: "146: biomedical technology companies", target: "146: highly volatile", fill: "#004040"},
{source: "146: common stock", target: "START_HERE", fill: "#004040"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Bombings</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Formally complain</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Provide shelter</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_product_development">New product development</a></td>
      <td>In business and engineering, new product development (NPD) covers the complete process of bringing a new product to market, renewing an existing product or introducing a product in a new market. A central aspect of NPD is product design, along with various business considerations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Central_Intelligence_Agency">Central Intelligence Agency</a></td>
      <td>The Central Intelligence Agency (CIA ), known informally as the Agency and historically as the Company, is a civilian foreign intelligence service of the federal government of the United States, officially tasked with gathering, processing, and analyzing national security information from around the world, primarily through the use of human intelligence (HUMINT) and performing covert actions. As a principal member of the United States Intelligence Community (IC), the CIA reports to the Director of National Intelligence and is primarily focused on providing intelligence for the President and Cabinet of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medication">Medication</a></td>
      <td>Meditation is a practice in which an individual uses a technique – such as mindfulness, or focusing the mind on a particular object, thought, or activity – to train attention and awareness, and achieve a mentally clear and emotionally calm and stable state.Meditation  is practiced in numerous religious traditions. The earliest records of meditation (dhyana) are found in the Upanishads of Hindu philosophy, and meditation plays a salient role in the contemplative repertoire of Buddhism and Hinduism.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Management_development">Management development</a></td>
      <td>Management development is the process by which managers learn and improve their management skills.\n\n\n== Background ==\nIn organisational development, management effectiveness is recognized as a determinant of organisational success.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development_hell">Development hell</a></td>
      <td>Development hell, development purgatory, and development limbo are media and software industry jargon for a project, concept, or idea that remains in development for an especially long time, often moving between different crews, scripts, game engines, or studios before it progresses to production, if it ever does. Projects in development hell are usually not released until development has reached a satisfying state worthy of being released, ready for production.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Professional_development">Professional development</a></td>
      <td>Professional development is learning to earn or maintain professional credentials such as academic degrees to formal coursework, attending conferences, and informal learning opportunities situated in practice. It has been described as intensive and collaborative, ideally incorporating an evaluative stage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirements_engineering">Requirements engineering</a></td>
      <td>Requirements engineering (RE) is the process of defining, documenting, and maintaining requirements in the engineering design process. It is a common role in systems engineering and software engineering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirements_analysis">Requirements analysis</a></td>
      <td>In systems engineering and software engineering, requirements analysis focuses on the tasks that determine the needs or conditions to meet the new or altered product or project, taking account of the possibly conflicting requirements of the various stakeholders, analyzing, documenting, validating and managing software or system requirements.Requirements analysis is critical to the success or failure of a systems or software project. The requirements should be documented, actionable, measurable, testable, traceable, related to identified business needs or opportunities, and defined to a level of detail sufficient for system design.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirements_elicitation">Requirements elicitation</a></td>
      <td>In requirements engineering, requirements elicitation is the practice of researching and discovering the requirements of a system from users, customers, and other stakeholders. The practice is also sometimes referred to as "requirement gathering".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Visa_requirements_for_United_States_citizens">Visa requirements for United States citizens</a></td>
      <td>As of 25 February 2022, Holders of a United States passport could travel to 186 countries and territories without a travel visa, or with a visa on arrival. The United States passport currently ranks 6th in terms of travel freedom (tied with the passports of Czech Republic, Greece, Malta, Norway, and the UK) according to the Henley Passport Index.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Functional_requirement">Functional requirement</a></td>
      <td>In software engineering and systems engineering, a functional requirement defines a function of a system or its component, where a function is described as a specification of behavior between inputs and outputs.Functional requirements may involve calculations, technical details, data manipulation and processing, and other specific functionality that define what a system is supposed to accomplish. Behavioral requirements describe all the cases where the system uses the functional requirements, these are captured in use cases.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/System_requirements_specification">System requirements specification</a></td>
      <td>A System Requirements Specification (SyRS) (abbreviated SysRS when need to be distinct from a software requirements specification (SRS)) is a structured collection of information that embodies the requirements of a system.A business analyst (BA), sometimes titled system analyst, is responsible for analyzing the business needs of their clients and stakeholders to help identify business problems and propose solutions. Within the systems development life cycle domain, the BA typically performs a liaison function between the business side of an enterprise and the information technology department or external service providers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Age_of_candidacy">Age of candidacy</a></td>
      <td>Age of candidacy is the minimum age at which a person can legally hold certain elected government offices. In many cases, it also determines the age at which a person may be eligible to stand for an election or be granted ballot access.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Copyright_law_of_France">Copyright law of France</a></td>
      <td>The droit d'auteur (or French copyright law) developed in the 18th century at the same time as copyright developed in the United Kingdom. Based on the "right of the author" (droit d'auteur) instead of on "copyright", its philosophy and terminology are different from those used in copyright law in common law jurisdictions.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Proprietary_software">Proprietary software</a></td>
      <td>Proprietary software, also known as non-free software or closed-source software, is computer software for which the software's publisher or another person reserves some licensing rights to use, modify, share modifications, or share the software, restricting user freedom with the software they lease. It is the opposite of open-source or free software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Moral_rights">Moral rights</a></td>
      <td>Moral rights are rights of creators of copyrighted works generally recognized in civil law jurisdictions and, to a lesser extent, in some common law jurisdictions.The moral rights include the right of attribution, the right to have a work published anonymously or pseudonymously, and the right to the integrity of the work. The preserving of the integrity of the work allows the author to object to alteration, distortion, or mutilation of the work that is "prejudicial to the author's honor or reputation".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Public_domain">Public domain</a></td>
      <td>The public domain consists of all the creative work to which no exclusive intellectual property rights apply. Those rights may have expired, been forfeited, expressly waived, or may be inapplicable.As examples, the works of William Shakespeare, Ludwig van Beethoven, Leonardo da Vinci and Georges Méliès are in the public domain either by virtue of their having been created before copyright existed, or by their copyright term having expired.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Proprietary_estoppel">Proprietary estoppel</a></td>
      <td>Proprietary estoppel is a legal claim, especially connected to English land law, which may arise in relation to rights to use the property of the owner, and may even be effective in connection with disputed transfers of ownership. Proprietary estoppel transfers rights if,\n\nsomeone is given a clear assurance that they will acquire a right over property,\nthey reasonably rely on the assurance, and,\nthey act substantially to their detriment on the strength of the assurance\nit would be unconscionable to go back on the assuranceIf these elements of assurance, reliance and detriment, and unconscionability are present, the usual remedy will be that the property will be transferred to the claimant, if the court views the reliance to warrant a claim in all the circumstances.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization">Commercialization</a></td>
      <td>Commercialization or commercialisation is the process of introducing a new product or production method into commerce—making it available on the market. The term often connotes especially entry into the mass market (as opposed to entry into earlier niche markets), but it also includes a move from the laboratory into (even limited) commerce.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_use_of_space">Commercial use of space</a></td>
      <td>Commercial use of space is the provision of goods or services of commercial value by using equipment sent into Earth orbit or outer space.  This phenomenon – aka Space Economy (or New Space Economy) – is accelerating cross-sector innovation processes combining the most advanced space and digital technologies to develop a broad portfolio of space-based services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_in_India">Clinical trials in India</a></td>
      <td>Clinical trials in India refers to clinical research in India in which researchers test drugs and other treatments on research participants. NDCTR 2019 and section 3.7.1 to 3.7.3 of ICMR guidelines requires that all researchers conducting a clinical trial must publicly document it in the Clinical Trials Registry - India.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sun_Pharma">Sun Pharma</a></td>
      <td>Sun Pharmaceutical Industries Limited (d/b/a Sun Pharma) is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs)  in more than 100 countries across the globe. It is largest pharma company in India and the fourth largest specialty generic pharmaceutical company in the world, with a total revenue of over US$4.5 billion as of June 2021.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_analysis">Competitor analysis</a></td>
      <td>Competitive analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors. This analysis provides both an offensive and defensive strategic context to identify opportunities and threats.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitors_for_the_Crown_of_Scotland">Competitors for the Crown of Scotland</a></td>
      <td>When the crown of Scotland became vacant in September 1290 on the death of the seven-year-old child Queen Margaret, 13 claimants to the throne came forward. Those with the most credible claims were John Balliol, Robert Bruce, John Hastings and Floris V, Count of Holland.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stock_market">Stock market</a></td>
      <td>A stock market, equity market, or share market is the aggregation of buyers and sellers of stocks (also called shares), which represent ownership claims on businesses; these may include securities listed on a public stock exchange, as well as stock that is only traded privately, such as shares of private companies which are sold to investors through equity crowdfunding platforms. Investment is usually made with an investment strategy in mind.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock_dividend">Common stock dividend</a></td>
      <td>A common stock dividend is the dividend paid to common stock owners from the profits of the company.  Like other dividends, the payout is in the form of either cash or stock.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preferred_stock">Preferred stock</a></td>
      <td>Preferred stock (also called preferred shares, preference shares, or simply preferreds) is a component of share capital that may have any combination of features not possessed by common stock, including properties of both an equity and a debt instrument, and is generally considered a hybrid instrument. Preferred stocks are senior (i.e., higher ranking) to common stock but subordinate to bonds in terms of claim (or rights to their share of the assets of the company, given that such assets are payable to the returnee stock bond) and may have priority over common stock (ordinary shares) in the payment of dividends and upon liquidation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Matthiola_incana">Matthiola incana</a></td>
      <td>Matthiola incana is a species of flowering plant in the cabbage family Brassicaceae. Common names include Brompton stock, common stock, hoary stock, ten-week stock, and gilly-flower.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Convertible_bond">Convertible bond</a></td>
      <td>In finance, a convertible bond or  convertible note or convertible debt (or a convertible debenture if it has a maturity of greater than 10 years) is a type of bond that the holder can convert into a specified number of shares of common stock in the issuing company or cash of equal value.  It is a hybrid security with debt- and equity-like features.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>ADVENTRX PHARMACEUTICALS INC      ITEM 1A RISK FACTORS     Risks Relating to Our Business          Readers and prospective investors in our securities should <font color="blue">carefully</font>     consider  the  following <font color="blue">risk factors</font> as well as the other information     contained or <font color="blue">incorporated by reference</font> in this report</td>
    </tr>
    <tr>
      <td>The risks and <font color="blue"><font color="blue">uncertainties</font> described</font> below are not the only ones     <font color="blue">facing us</font></td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>risks and <font color="blue">uncertainties</font> that <font color="blue">management</font> is not aware     of or <font color="blue">focused on</font> or that <font color="blue">management</font> currently deems <font color="blue">immaterial may also</font>     impair our business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>This report is qualified in its <font color="blue">entirety by</font>     these <font color="blue">risk factors</font></td>
    </tr>
    <tr>
      <td>If any of the <font color="blue">following risks actually</font> occur, the Company’s financial     condition  and results of <font color="blue">operations</font> could be <font color="blue">materially</font> and <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td>If this were to happen, the value of the Company’s securities     could  decline  <font color="blue"><font color="blue">significant</font>ly</font>,  and you <font color="blue">could lose</font> all or part of your     <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>We have a substantial <font color="blue">accumulated deficit</font> and limited working capital</td>
    </tr>
    <tr>
      <td>We had an <font color="blue">accumulated deficit</font> of dlra59cmam964cmam840 as of <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>Since  we  presently  have  no source of revenues and are committed to     continuing  our  <font color="blue">product research</font> and <font color="blue">development</font> program, <font color="blue">significant</font>     <font color="blue"><font color="blue">expenditure</font>s</font> and <font color="blue">losses will continue until <font color="blue">development</font></font> of <font color="blue">new products</font> is     completed and <font color="blue">such products</font> have been clinically tested, approved by the FDA     or other <font color="blue"><font color="blue">regulatory</font> agencies</font> and <font color="blue"><font color="blue">successfully</font> marketed</font></td>
    </tr>
    <tr>
      <td>In addition, we fund     our <font color="blue">operations</font> primarily through the sale of <font color="blue">equity securities</font>, and have had     limited working capital for our <font color="blue">product <font color="blue">development</font></font> and other <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>We     do not believe that <font color="blue"><font color="blue">debt financing</font> from financial <font color="blue">institution</font>s will</font> be     <font color="blue">available until at least</font> the time that one of our products is approved for     <font color="blue">commercial production</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">no current product sales revenues</font> or profits</td>
    </tr>
    <tr>
      <td>We  have  devoted our resources to developing a <font color="blue">new generation</font> of     <font color="blue">therapeutic</font>  <font color="blue">drug product</font>s, but <font color="blue">such products</font> cannot be <font color="blue">marketed until</font>     <font color="blue">clinical testing</font> is completed and <font color="blue"><font color="blue">government</font>al approvals</font> have been obtained</td>
    </tr>
    <tr>
      <td>Accordingly, there is <font color="blue">no current source</font> of revenues, much <font color="blue">less profits</font>, to     sustain our present <font color="blue">activities</font>, and <font color="blue">no revenues will likely</font> be available     until, and unless, the <font color="blue">new products</font> are clinically tested, approved by the     FDA or other <font color="blue"><font color="blue">regulatory</font> agencies</font> and <font color="blue"><font color="blue">successfully</font> marketed</font>, either by us or     a <font color="blue">marketing partner</font>, an <font color="blue">outcome which</font> we are not able to guarantee</td>
    </tr>
    <tr>
      <td>13       _________________________________________________________________    [73]Table of <font color="blue">Contents       </font>It is uncertain that we will have access to <font color="blue">future capital</font></td>
    </tr>
    <tr>
      <td>We do not expect to generate positive cash flow from <font color="blue">operations</font> for at     least the <font color="blue">next <font color="blue">several years</font></font></td>
    </tr>
    <tr>
      <td>As a result, substantial <font color="blue">additional</font> equity or     <font color="blue">debt financing</font> for research and <font color="blue">development</font> or clinical <font color="blue">development</font> will be     required to fund our <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Although we have <font color="blue">raised equity financing</font> in     the past, including in April 2004 and July 2005, we cannot be certain that     we  will  be able to continue to obtain <font color="blue">such financing on</font> favorable or     satisfactory terms, if at all, or that it will be sufficient to meet our     cash  <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Any  <font color="blue">additional</font>  <font color="blue">equity financing could</font> result in     substantial dilution to <font color="blue">stockholders</font>, and <font color="blue">debt financing</font>, if available,     <font color="blue">would likely involve restrictive covenants</font> that <font color="blue">preclude us from</font> making     <font color="blue"><font color="blue">distribution</font>s</font>  to  <font color="blue">stockholders</font> and taking other <font color="blue">actions beneficial</font> to     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">adequate funds</font> are not available, we may be required to     delay or reduce the scope of our drug <font color="blue">development</font> program or attempt to     continue  <font color="blue">development</font> by entering into <font color="blue">arrangements with</font> collaborative     partners or others that may require us to <font color="blue">relinquish</font> some or all of our     rights to <font color="blue">proprietary drugs</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">inability</font> to <font color="blue">adequately</font> and <font color="blue">timely fund</font> our     capital <font color="blue">requirements</font> would have a material adverse effect on us</td>
    </tr>
    <tr>
      <td>We are not certain that we will be successful in the <font color="blue">development</font> of our drug     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>The successful <font color="blue">development</font> of any new drug is <font color="blue">highly uncertain</font> and is     subject to a number of <font color="blue"><font color="blue"><font color="blue">significant</font> risk</font>s</font></td>
    </tr>
    <tr>
      <td>Our drug <font color="blue">candidates</font>, all of which     are in a <font color="blue">development</font> stage, require <font color="blue">significant</font>, time-consuming and costly     <font color="blue">development</font>, testing and <font color="blue"><font color="blue">regulatory</font> clearance</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">process typically</font> takes     <font color="blue">several years</font> and can require <font color="blue">substantially</font> more time</td>
    </tr>
    <tr>
      <td>Risks include, among     others,  the <font color="blue">possibility</font> that a <font color="blue">drug candidate will</font> (i) be found to be     <font color="blue">in<font color="blue">effective</font></font> or unacceptably toxic, (ii) have unacceptable side effects,     (iii) fail to receive <font color="blue">necessary</font> <font color="blue"><font color="blue">regulatory</font> clearance</font>s, (iv) not achieve     broad <font color="blue">market <font color="blue">acceptance</font></font>, (v) be subject to <font color="blue">competition from <font color="blue">third parties</font></font>     who <font color="blue">may market equivalent</font> or superior products, (vi) be <font color="blue">affected by third</font>     parties holding <font color="blue">proprietary rights</font> that will <font color="blue">preclude us from</font> marketing a     <font color="blue">drug product</font>, or (vii) not be able to be <font color="blue"><font color="blue">manufacture</font>d by <font color="blue">manufacture</font>rs</font> in a     <font color="blue">timely manner</font> in <font color="blue">accordance with</font> required standards of quality</td>
    </tr>
    <tr>
      <td>There can be     no assurance that the <font color="blue">development</font> of our drug <font color="blue">candidates</font> will demonstrate     the efficacy and safety of our drug <font color="blue">candidates</font> as <font color="blue">therapeutic</font> drugs, or,     even if <font color="blue">demonstrated</font>, that <font color="blue">there will</font> be <font color="blue">sufficient advantages</font> to their use     over other drugs or <font color="blue">treatments</font> so as to render the <font color="blue">drug product</font> <font color="blue">commercially</font>     viable</td>
    </tr>
    <tr>
      <td>We have <font color="blue">also chosen</font> to <font color="blue">terminate licenses</font> of     some drug <font color="blue">candidates</font> that were not <font color="blue">showing sufficient promise</font> to justify     <font color="blue">continued expense</font> and <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>In the event that we are not successful     in developing and <font color="blue">commercializing</font> one or more drug <font color="blue">candidates</font>, investors are     likely to realize a loss of their entire <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">been delayed at certain times</font> in the past in the <font color="blue">development</font> of     our  drug  <font color="blue">products by</font> limited funding</td>
    </tr>
    <tr>
      <td>In addition, if certain of our     scientific and <font color="blue">technical personnel resigned at</font> or about the same time, the     <font color="blue">development</font>  of  our <font color="blue">drug product</font>s would probably be <font color="blue">delayed until new</font>     personnel were hired and <font color="blue">became familiar with</font> the <font color="blue">development</font> programs</td>
    </tr>
    <tr>
      <td>Positive results in preclinical and <font color="blue"><font color="blue">clinical trial</font>s</font> do not ensure that     future <font color="blue"><font color="blue">clinical trial</font>s</font> will be successful or that drug <font color="blue">candidates</font> will     receive all <font color="blue"><font color="blue">necessary</font> <font color="blue"><font color="blue">regulatory</font> approvals</font></font> for the marketing, <font color="blue">distribution</font>     or sale of such drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td><font color="blue">Success  </font>in  preclinical and <font color="blue"><font color="blue">clinical trial</font>s</font> does not ensure that     large-scale  clinical  trials will be successful</td>
    </tr>
    <tr>
      <td>Clinical results are     <font color="blue">frequently susceptible</font> to <font color="blue">varying interpretations</font> that may delay, limit or     <font color="blue">prevent <font color="blue"><font color="blue">regulatory</font> approvals</font></font></td>
    </tr>
    <tr>
      <td>The length of time <font color="blue">necessary</font> to complete     <font color="blue"><font color="blue">clinical trial</font>s</font> and to submit an <font color="blue">application</font> for <font color="blue">marketing approval</font> for a     <font color="blue">final decision by</font> a <font color="blue">regulatory</font> authority varies <font color="blue"><font color="blue">significant</font>ly</font> and may be     <font color="blue">difficult</font> to predict</td>
    </tr>
    <tr>
      <td>In the past, we have terminated licenses of drug     <font color="blue">candidates</font> when our pre<font color="blue"><font color="blue">clinical trial</font>s</font> did not support or verify earlier     preclinical  data</td>
    </tr>
    <tr>
      <td>There  is  a <font color="blue"><font color="blue">significant</font> risk</font> that any of our drug     <font color="blue">candidates</font> could fail to show satisfactory results in <font color="blue">continued trials</font>, and     would not justify further <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>14       _________________________________________________________________    [74]Table of <font color="blue">Contents       </font>We <font color="blue"><font color="blue">will face intense</font> competition from</font> other companies in the <font color="blue">pharmaceutical</font>     industry</td>
    </tr>
    <tr>
      <td>We are engaged in a segment of the <font color="blue">pharmaceutical</font> industry that is     <font color="blue">highly <font color="blue">competitive</font></font> and rapidly changing</td>
    </tr>
    <tr>
      <td>If <font color="blue">successfully</font> developed and     approved,  any of our drug <font color="blue">candidates</font> will likely <font color="blue">compete with</font> several     <font color="blue">existing therapies</font></td>
    </tr>
    <tr>
      <td>CoFactor, our leading drug candidate, would likely     <font color="blue">compete against</font> a well-established product, <font color="blue">leucovorin</font></td>
    </tr>
    <tr>
      <td>In addition, there     are  numerous  companies  with  a  focus in oncology and/or anti-viral     <font color="blue">therapeutic</font>s that are pursuing the <font color="blue">development</font> of <font color="blue">pharmaceutical</font>s that     target the <font color="blue">same diseases as</font> are <font color="blue">targeted by</font> the drugs being developed by us</td>
    </tr>
    <tr>
      <td>We anticipate that we <font color="blue">will face intense</font> and <font color="blue">increasing competition</font> in the     future as <font color="blue">new products</font> enter the market and <font color="blue">advanced <font color="blue">technologies</font> become</font>     available</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> that <font color="blue">existing products</font> or <font color="blue">new products</font> developed     <font color="blue">by <font color="blue">competitors</font> will</font> not be more <font color="blue">effective</font>, or more <font color="blue">effective</font>ly marketed and     sold than those we may market and sell</td>
    </tr>
    <tr>
      <td><font color="blue">Competitive </font><font color="blue">products may</font> render our     <font color="blue">drugs obsolete</font> or <font color="blue">non<font color="blue">competitive</font> prior</font> to our recovery of <font color="blue">development</font> and     <font color="blue"><font color="blue">commercialization</font> expenses</font></td>
    </tr>
    <tr>
      <td>Many of our likely <font color="blue">competitors</font>, such as Merck and Pfizer, will also     have <font color="blue"><font color="blue">significant</font>ly</font> greater financial, technical and <font color="blue">human resources</font> and will     likely be <font color="blue">better equipped</font> to develop, <font color="blue">manufacture</font> and <font color="blue">market products</font></td>
    </tr>
    <tr>
      <td>In     addition, many of these <font color="blue">competitors</font> have extensive experience in preclinical     testing and <font color="blue"><font color="blue">clinical trial</font>s</font>, obtaining FDA and other <font color="blue"><font color="blue">regulatory</font> approvals</font>     and <font color="blue">manufacturing</font> and marketing <font color="blue">pharmaceutical</font> products</td>
    </tr>
    <tr>
      <td>A number of these     <font color="blue">competitors</font> also have products that have <font color="blue">been approved</font> or are in late-stage     <font color="blue">development</font>  and  operate  large, well-funded research and <font color="blue">development</font>     programs</td>
    </tr>
    <tr>
      <td>Smaller <font color="blue">companies may also prove</font> to be <font color="blue">significant</font> <font color="blue">competitors</font>,     <font color="blue">particularly through collaborative <font color="blue">arrangements with</font></font> large <font color="blue">pharmaceutical</font>     and <font color="blue">bio<font color="blue">technology</font> companies</font></td>
    </tr>
    <tr>
      <td>Furthermore, academic <font color="blue">institution</font>s, <font color="blue">government</font>     agencies and other public and <font color="blue">private research <font color="blue">organization</font>s</font> are becoming     <font color="blue">increasingly aware</font> of the <font color="blue">commercial value</font> of their <font color="blue">inventions</font> and are     actively  seeking to <font color="blue">commercialize</font> the <font color="blue">technology</font> they have developed</td>
    </tr>
    <tr>
      <td><font color="blue">Companies  </font>such as Gilead, Roche and GlaxoSmithKline all have drugs in     <font color="blue">various stages</font> of <font color="blue">development</font> that could become <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>Accordingly,     <font color="blue">competitors</font>  may  succeed  in <font color="blue">commercializing</font> products more rapidly or     <font color="blue">effective</font>ly than us, which would have a material adverse effect on us</td>
    </tr>
    <tr>
      <td>There is no assurance that our <font color="blue">products will</font> have <font color="blue">market <font color="blue">acceptance</font></font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend</font> in substantial part on the extent to which a     <font color="blue">drug product</font>, if <font color="blue">eventually approved</font> for <font color="blue">commercial <font color="blue">distribution</font></font>, achieves     <font color="blue">market <font color="blue">acceptance</font></font></td>
    </tr>
    <tr>
      <td>The degree of <font color="blue">market <font color="blue">acceptance</font></font> will depend upon a number     of factors, including (i) the receipt and scope of <font color="blue"><font color="blue">regulatory</font> approvals</font>,     (ii) the <font color="blue">establishment</font> and <font color="blue">demonstration</font> in the <font color="blue">medical community</font> of the     safety  and  efficacy of a <font color="blue">drug product</font>, (iii) the product’s potential     <font color="blue">advantages over existing treatment methods</font> and (iv) <font color="blue">reimbursement</font> policies     of <font color="blue">government</font> and <font color="blue"><font color="blue">third party</font> payors</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> or guarantee that     physicians, patients, healthcare insurers or <font color="blue">maintenance <font color="blue">organization</font>s</font>, or     the <font color="blue">medical community</font> in general, will accept or utilize any of our drug     products</td>
    </tr>
    <tr>
      <td>The <font color="blue">unavailability</font> of <font color="blue"><font color="blue">health care</font> <font color="blue">reimbursement</font></font> for any of our <font color="blue">products will</font>     likely <font color="blue">adversely</font> impact our ability to <font color="blue">effective</font>ly market <font color="blue">such products</font> and     whether <font color="blue"><font color="blue">health care</font> <font color="blue">reimbursement</font></font> will be available for any of our products     is uncertain</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">commercialize</font> our <font color="blue">technology</font> <font color="blue">successfully</font> will depend in     part on the extent to <font color="blue">which <font color="blue">reimbursement</font></font> for the costs of <font color="blue">such products</font> and     related <font color="blue">treatments</font> will be available from <font color="blue">government</font> health administration     <font color="blue">authorities</font>,  private  health  insurers  and other third-party payors</td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font><font color="blue">uncertainty</font> exists as to the <font color="blue"><font color="blue">reimbursement</font> status</font> of newly     <font color="blue">approved medical products</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot guarantee</font> that adequate third-party     insurance coverage will be available for us to establish and maintain price     levels  sufficient  for  <font color="blue">realization</font>  of  an <font color="blue"><font color="blue">appropriate</font> return on</font> our     <font color="blue">investment</font>s in developing <font color="blue">new therapies</font></td>
    </tr>
    <tr>
      <td>If we are successful in getting FDA     approval  for  CoFactor,  we will be <font color="blue">competing against</font> a <font color="blue">generic drug</font>,     <font color="blue">leucovorin</font>,  which has a <font color="blue">lower cost</font> and a long, established history of     <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td><font color="blue">Receiving </font>sufficient <font color="blue">reimbursement</font> for <font color="blue">purchase costs</font> of     CoFactor will be <font color="blue">necessary</font> to make it cost <font color="blue">effective</font> and <font color="blue"><font color="blue">competitive</font> versus</font>     the established drug, <font color="blue">leucovorin</font></td>
    </tr>
    <tr>
      <td>Government, <font color="blue">private health insurers</font>, and     other third-party payors are <font color="blue">increasingly attempting</font> to <font color="blue">contain <font color="blue">health care</font></font>     <font color="blue">costs by limiting both coverage</font> and the level of <font color="blue">reimbursement</font> for new     <font color="blue">therapeutic</font> products approved for marketing by the FDA Accordingly, even if     coverage  and <font color="blue">reimbursement</font> are provided by <font color="blue">government</font>, private health     insurers,  and  third-party payors for use of our products, the market     <font color="blue">acceptance</font> of these <font color="blue">products would</font> be <font color="blue">adversely</font> affected if the amount of     <font color="blue">reimbursement</font>  available  for  the  use  of our <font color="blue">therapies proved</font> to be     unprofitable for <font color="blue"><font color="blue">health care</font> providers</font></td>
    </tr>
    <tr>
      <td>15       _________________________________________________________________    [75]Table of <font color="blue">Contents       </font>Uncertainties related to <font color="blue"><font color="blue">health care</font> reform measures may affect</font> our success</td>
    </tr>
    <tr>
      <td>There have been some federal and state proposals in the past to subject     the pricing of <font color="blue">health care</font> goods and services, including <font color="blue">prescription drugs</font>,     to <font color="blue">government</font> control and to make other changes to the US <font color="blue">health care</font>     system</td>
    </tr>
    <tr>
      <td>None of the <font color="blue">proposals seems</font> to have affected any of the drugs in our     programs</td>
    </tr>
    <tr>
      <td>However, it is uncertain if <font color="blue">future legislative proposals would</font> be     adopted that <font color="blue">might affect</font> the drugs in our programs or what <font color="blue">actions federal</font>,     state, or <font color="blue">private payors</font> for <font color="blue">health care</font> treatment and <font color="blue">services may</font> take in     response to any such <font color="blue">health care</font> reform proposals or <font color="blue">legislation</font></td>
    </tr>
    <tr>
      <td>Any such     health  care  reforms  could  have  a  material  adverse effect on the     <font color="blue">marketability</font> of any drugs for which we ultimately require FDA approval</td>
    </tr>
    <tr>
      <td>Further testing of our drug <font color="blue">candidates</font> will be required and there is no     assurance of FDA approval</td>
    </tr>
    <tr>
      <td>The FDA and comparable agencies in foreign countries impose substantial     <font color="blue">requirements</font> upon the <font color="blue">introduction</font> of medical products, through lengthy and     detailed <font color="blue">laboratory</font> and <font color="blue">clinical testing</font> procedures, sampling <font color="blue">activities</font> and     other  costly  and  time-consuming  procedures</td>
    </tr>
    <tr>
      <td><font color="blue">Satisfaction </font>of these     <font color="blue">requirements</font> typically takes <font color="blue">several years</font> or more and varies <font color="blue">substantially</font>     based upon the type, <font color="blue">complexity</font>, and novelty of the product</td>
    </tr>
    <tr>
      <td>The effect of <font color="blue">government</font> regulation and the need for FDA <font color="blue">approval will</font>     <font color="blue">delay marketing</font> of <font color="blue">new products</font> for a considerable period of time, impose     <font color="blue">costly procedures upon</font> our <font color="blue">activities</font>, and provide an advantage to larger     companies that <font color="blue"><font color="blue">compete with</font> us</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that the FDA or     other <font color="blue">regulatory</font> approval for any products developed by us will be granted     on a <font color="blue">timely basis</font> or at all</td>
    </tr>
    <tr>
      <td>Any such delay in obtaining or failure to     obtain, such approvals would <font color="blue">materially</font> and <font color="blue">adversely</font> affect the marketing     of  any contemplated products and the ability to <font color="blue">earn product revenue</font></td>
    </tr>
    <tr>
      <td>Further, regulation of <font color="blue">manufacturing</font> <font color="blue">facilities</font> by state, local, and other     <font color="blue">authorities</font> is subject to change</td>
    </tr>
    <tr>
      <td>Any <font color="blue">additional</font> regulation could result in     <font color="blue">limitations</font>  or  <font color="blue">restrictions</font>  on  our  ability  to utilize any of our     <font color="blue">technologies</font>, thereby <font color="blue">adversely</font> affecting our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Human <font color="blue">pharmaceutical</font> products are subject to <font color="blue">rigorous preclinical</font>     testing and <font color="blue"><font color="blue">clinical trial</font>s</font> and other <font color="blue">approval procedures mandated by</font> the     FDA and foreign <font color="blue">regulatory</font> <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>Various federal and <font color="blue">foreign statutes</font>     and  <font color="blue">regulations</font>  also  govern or influence the <font color="blue">manufacturing</font>, safety,     labeling, storage, record keeping and marketing of <font color="blue">pharmaceutical</font> products</td>
    </tr>
    <tr>
      <td>The process of obtaining these approvals and the <font color="blue">subsequent compliance with</font>     <font color="blue">appropriate</font> US and <font color="blue">foreign statutes</font> and <font color="blue">regulations</font> are time-consuming and     require  the  <font color="blue">expenditure</font> of substantial resources</td>
    </tr>
    <tr>
      <td>In addition, these     <font color="blue">requirements</font> and <font color="blue">processes vary widely from country</font> to country</td>
    </tr>
    <tr>
      <td>Among the <font color="blue">uncertainties</font> and risks of the FDA approval process are the     following: (i) the <font color="blue">possibility</font> that studies and <font color="blue"><font color="blue">clinical trial</font>s</font> will fail to     prove the safety and efficacy of the drug, or that any <font color="blue">demonstrated</font> efficacy     will be so limited as to <font color="blue"><font color="blue">significant</font>ly</font> reduce or <font color="blue">altogether</font> eliminate the     <font color="blue">acceptability</font> of the drug in the marketplace, (ii) the <font color="blue">possibility</font> that the     costs of <font color="blue">development</font>, which can far exceed the best of estimates, may render     <font color="blue">commercialization</font>  of  the  drug  <font color="blue">marginally</font>  profitable or <font color="blue">altogether</font>     unprofitable, and (iii) the <font color="blue">possibility</font> that the amount of time required for     FDA approval of a <font color="blue">drug may extend</font> for <font color="blue">years beyond</font> that which is <font color="blue">originally</font>     estimated</td>
    </tr>
    <tr>
      <td>In addition, the FDA or similar foreign <font color="blue">regulatory</font> <font color="blue">authorities</font>     may require <font color="blue">additional</font> <font color="blue"><font color="blue">clinical trial</font>s</font>, which could result in increased     costs and <font color="blue">significant</font> <font color="blue">development</font> delays</td>
    </tr>
    <tr>
      <td>Delays or <font color="blue">rejections</font> may also be     <font color="blue">encountered</font>  based upon changes in FDA policy and the <font color="blue">establishment</font> of     <font color="blue">additional</font> <font color="blue">regulations</font> during the period of <font color="blue">product <font color="blue">development</font></font> and FDA     review</td>
    </tr>
    <tr>
      <td>Similar delays or <font color="blue">rejections</font> may be <font color="blue">encountered</font> in other countries</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend</font> on licenses and <font color="blue">proprietary rights</font> we receive from     other parties, and on any patents we may obtain</td>
    </tr>
    <tr>
      <td>Our  success  will  depend  in  large part on our ability and our     <font color="blue">licensors</font>’  ability to (i) maintain license and <font color="blue"><font color="blue">patent protection</font> with</font>     respect  to their <font color="blue">drug product</font>s, (ii) defend patents and licenses once     obtained, (iii) maintain <font color="blue">trade secrets</font>, (iv) operate <font color="blue">without infringing upon</font>     the patents and <font color="blue">proprietary rights</font> of others and (iv) obtain <font color="blue">appropriate</font>     licenses  to  patents  or  <font color="blue">proprietary rights</font> held <font color="blue">by <font color="blue">third parties</font></font> if     <font color="blue">infringement</font>  would  otherwise  occur, both in the US and in foreign     countries</td>
    </tr>
    <tr>
      <td>We have obtained licenses to patents and other <font color="blue">proprietary rights</font>     from the University of Southern California and SD Pharmaceuticals, Inc</td>
    </tr>
    <tr>
      <td>The <font color="blue">patent positions</font> of <font color="blue">pharmaceutical</font> companies, including ours, are     uncertain and <font color="blue">involve complex legal</font> and factual questions</td>
    </tr>
    <tr>
      <td>There is no     guarantee that we or our <font color="blue">licensors</font> have or will develop or obtain the rights     to products or processes that are patentable, that <font color="blue">patents will issue from</font>     any of the pending <font color="blue">application</font>s or that claims                                         16       _________________________________________________________________    [76]Table of <font color="blue">Contents       </font><font color="blue">allowed will</font> be sufficient to protect the <font color="blue">technology</font> licensed to us</td>
    </tr>
    <tr>
      <td>In     addition, we cannot be certain that any <font color="blue">patents issued</font> to or <font color="blue">licensed by us</font>     will not be challenged, invalidated, infringed or <font color="blue">circumvented</font>, or that the     rights granted thereunder will provide <font color="blue">competitive</font> disadvantages to us</td>
    </tr>
    <tr>
      <td>Litigation,  which  could result in substantial cost, may also be     <font color="blue">necessary</font> to enforce any patents to which we have rights, or to determine     the scope, validity and <font color="blue">unenforceability</font> of other parties’ proprietary     rights, which may affect our rights</td>
    </tr>
    <tr>
      <td>US patents carry a <font color="blue">presumption</font> of     validity and <font color="blue">generally</font> can be <font color="blue">invalidated only through clear</font> and convincing     evidence</td>
    </tr>
    <tr>
      <td>There can be no assurance that our <font color="blue">licensed patents would</font> be held     valid by a court or <font color="blue">administrative</font> body or that an alleged <font color="blue">infringer would</font>     be  found  to  be  infringing</td>
    </tr>
    <tr>
      <td>The mere <font color="blue">uncertainty</font> resulting from the     <font color="blue">institution</font>  and  <font color="blue">continuation</font> of any <font color="blue">technology</font>-related <font color="blue">litigation</font> or     <font color="blue">interference proceeding could</font> have a material adverse effect on us pending     resolution of the <font color="blue">disputed matters</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may also rely on unpatented <font color="blue">trade secrets</font></font> and know-how to maintain     our  <font color="blue">competitive</font>  position,  which  we  seek  to  protect, in part, by     confidentiality <font color="blue">agreement</font>s with employees, <font color="blue">consultants</font> and others</td>
    </tr>
    <tr>
      <td>There can     be no assurance that these <font color="blue"><font color="blue">agreement</font>s will</font> not be breached or terminated,     that we will have <font color="blue">adequate remedies</font> for any breach, or that <font color="blue">trade secrets</font>     will  not  otherwise  become  known  or be <font color="blue">in<font color="blue">dependent</font>ly discovered by</font>     <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">license <font color="blue">agreement</font>s</font> can be terminated in the event of a breach</td>
    </tr>
    <tr>
      <td>The  license  <font color="blue">agreement</font>s  pursuant  to  which we license our core     <font color="blue">technologies</font>  for  our  potential  <font color="blue">drug product</font>s permit the <font color="blue">licensors</font>,     <font color="blue">respectively</font> the University of Southern California and SD Pharmaceuticals,     Inc, to terminate the <font color="blue">agreement</font> under certain <font color="blue">circumstances</font>, such as the     failure  by us to use our reasonable best efforts to <font color="blue">commercialize</font> the     subject drug or the occurrence of any other uncured material <font color="blue">breach by us</font></td>
    </tr>
    <tr>
      <td>The  license  <font color="blue">agreement</font>s  also  provide that the licensor is primarily     responsible for obtaining <font color="blue">patent protection</font> for the <font color="blue">technology</font> licensed, and     we  are  required to reimburse the licensor for the costs it incurs in     performing these <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">license <font color="blue">agreement</font>s</font> also require the payment     of <font color="blue">specified royalties</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">inability</font> or failure to observe these terms or     pay  these  costs  or <font color="blue">royalties could</font> result in the <font color="blue">termination</font> of the     applicable license <font color="blue">agreement</font> in <font color="blue">certain cases</font></td>
    </tr>
    <tr>
      <td>In the past, we have let     lapse certain licenses for drug <font color="blue">candidates</font> when we determined that the     expense and risk of continued <font color="blue">development</font> outweighed the likely benefits of     that continued <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">termination</font> of any license <font color="blue">agreement</font> could     have a material adverse effect on us</td>
    </tr>
    <tr>
      <td><font color="blue">Protecting </font>our <font color="blue">proprietary rights</font> is <font color="blue">difficult</font> and costly</td>
    </tr>
    <tr>
      <td>The <font color="blue">patent positions</font> of <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font> companies</font> can     be  highly  uncertain and <font color="blue">involve complex legal</font> and factual questions</td>
    </tr>
    <tr>
      <td>Accordingly,  we <font color="blue">cannot predict</font> the breadth of claims allowed in these     companies’ patents or whether we may infringe or be infringing these claims</td>
    </tr>
    <tr>
      <td>Although we have not <font color="blue">been notified</font> of any patent <font color="blue">infringement</font>, nor notified     others of patent <font color="blue">infringement</font>, such patent disputes are common and could     preclude the <font color="blue">commercialization</font> of our products</td>
    </tr>
    <tr>
      <td>Patent <font color="blue">litigation</font> is costly     in its own right and could subject us to <font color="blue">significant</font> liabilities to third     parties</td>
    </tr>
    <tr>
      <td>In addition, an <font color="blue">adverse decision could force us</font> to either obtain     third-party licenses at a material cost or <font color="blue">cease using</font> the <font color="blue">technology</font> or     product in dispute</td>
    </tr>
    <tr>
      <td>We may be unable to retain <font color="blue">skilled personnel</font> and maintain <font color="blue">key <font color="blue">relationships</font></font></td>
    </tr>
    <tr>
      <td>The success of our business depends, in large part, on our ability to     attract  and  retain highly qualified <font color="blue">management</font>, scientific and other     personnel,  and  on  our  ability  to  develop  and maintain important     <font color="blue">relationships</font>  with  leading research <font color="blue">institution</font>s and <font color="blue">consultants</font> and     advisors</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>for these types of personnel and <font color="blue">relationships</font> is     intense  from  numerous  <font color="blue">pharmaceutical</font>  and  <font color="blue">bio<font color="blue">technology</font> companies</font>,     <font color="blue">universities</font> and other research <font color="blue">institution</font>s</td>
    </tr>
    <tr>
      <td>We are <font color="blue">currently <font color="blue">dependent</font></font>     upon  our  scientific  staff,  which has a <font color="blue">deep background</font> in our drug     <font color="blue">candidates</font> and the <font color="blue">ongoing preclinical</font> and <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">Recruiting </font>and     retaining senior employees with relevant drug <font color="blue">development</font> experience in     oncology and anti-viral <font color="blue">therapeutic</font>s is costly and time-consuming</td>
    </tr>
    <tr>
      <td>There can     be no assurance that we will be able to attract and retain <font color="blue">such individuals</font>     on an <font color="blue">uninterrupted basis</font> and <font color="blue">on <font color="blue">commercially</font></font> acceptable terms, and the     failure to do so could have a material adverse effect on us by <font color="blue"><font color="blue">significant</font>ly</font>     <font color="blue">delaying one</font> or more of our drug <font color="blue">development</font> programs</td>
    </tr>
    <tr>
      <td>The loss of any of     our <font color="blue">senior executive officers</font>, including our <font color="blue">chief executive officer</font> and     <font color="blue">chief financial officer</font>, in particular, could have a material adverse effect     on the company and the market for our <font color="blue">common stock</font>, particularly if such     loss was abrupt or unexpected</td>
    </tr>
    <tr>
      <td>We do not have non-competition <font color="blue">agreement</font>s     with any of our employees</td>
    </tr>
    <tr>
      <td>17       _________________________________________________________________    [77]Table of <font color="blue">Contents       </font>We currently have <font color="blue">no sales capability</font>, and limited <font color="blue">marketing capability</font></td>
    </tr>
    <tr>
      <td>We currently do not have <font color="blue">sales personnel</font></td>
    </tr>
    <tr>
      <td>We have limited marketing and     business <font color="blue">development</font> personnel</td>
    </tr>
    <tr>
      <td>We will have to develop a sales force, or     rely on <font color="blue">marketing partner</font>s or other <font color="blue"><font color="blue">arrangements with</font> <font color="blue">third parties</font></font> for the     marketing, <font color="blue">distribution</font> and sale of any <font color="blue">drug product</font> which is ready for     <font color="blue">distribution</font></td>
    </tr>
    <tr>
      <td>There is no guarantee that we will be able to establish     marketing, <font color="blue">distribution</font> or <font color="blue">sales <font color="blue">capabilities</font></font> or make <font color="blue">arrangements with</font>     <font color="blue">third parties</font> to perform those <font color="blue">activities</font> on terms satisfactory to us, or     that  any  internal  <font color="blue">capabilities</font>  or <font color="blue"><font color="blue">third party</font> arrangements will</font> be     cost-<font color="blue">effective</font></td>
    </tr>
    <tr>
      <td>In addition, any <font color="blue">third parties</font> with which we <font color="blue">may establish marketing</font>,     <font color="blue">distribution</font>  or  sales arrangements may have <font color="blue">significant</font> control over     <font color="blue">important aspects</font> of the <font color="blue">commercialization</font> of a <font color="blue">drug product</font>, including     market identification, marketing methods, pricing, composition of sales     force and promotional <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that we will be     able to control the amount and timing of resources that any <font color="blue"><font color="blue">third party</font> may</font>     devote to our products or prevent any <font color="blue"><font color="blue">third party</font> from pursuing alternative</font>     <font color="blue">technologies</font> or products that could result in the <font color="blue">development</font> of products     that <font color="blue">compete with</font>, or the withdrawal of support for, our products</td>
    </tr>
    <tr>
      <td>We do not have <font color="blue">manufacturing</font> <font color="blue">capabilities</font> and may not be able to <font color="blue">efficiently</font>     develop <font color="blue">manufacturing</font> <font color="blue">capabilities</font> or contract for <font color="blue">such services from third</font>     parties <font color="blue">on <font color="blue">commercially</font></font> acceptable terms</td>
    </tr>
    <tr>
      <td>We do not have any <font color="blue">manufacturing</font> capacity</td>
    </tr>
    <tr>
      <td>When and if required, we     will seek to establish <font color="blue">relationships</font> with third-party <font color="blue">manufacture</font>rs for the     <font color="blue">manufacture</font> of <font color="blue">clinical trial</font> material and the <font color="blue">commercial production</font> of drug     <font color="blue">products as</font> we have with our current <font color="blue">manufacturing</font> partners</td>
    </tr>
    <tr>
      <td>There can be no     assurance that we will be able to establish <font color="blue">relationships</font> with third-party     <font color="blue">manufacture</font>rs  on  <font color="blue">commercially</font>  acceptable  terms or that third-party     <font color="blue">manufacture</font>rs will be able to <font color="blue">manufacture</font> a <font color="blue">drug product</font> on a cost-<font color="blue">effective</font>     basis in <font color="blue">commercial quantities under</font> good <font color="blue">manufacturing</font> practices mandated     by the FDA or other <font color="blue">regulatory</font> matters</td>
    </tr>
    <tr>
      <td>The dependence upon <font color="blue">third parties</font> for the <font color="blue">manufacture</font> of <font color="blue">products may</font>     <font color="blue">adversely</font> affect future costs and the ability to develop and <font color="blue">commercialize</font> a     <font color="blue">drug product</font> on a timely and <font color="blue">competitive</font> basis</td>
    </tr>
    <tr>
      <td>Further, there can be no     assurance that <font color="blue">manufacturing</font> or <font color="blue">quality control problems will</font> not arise in     <font color="blue">connection with</font> the <font color="blue">manufacture</font> of our <font color="blue">drug product</font>s or that <font color="blue">third party</font>     <font color="blue">manufacture</font>rs will be able to maintain the <font color="blue">necessary</font> <font color="blue">government</font>al licenses     and  approvals to continue <font color="blue">manufacturing</font> <font color="blue">such products</font></td>
    </tr>
    <tr>
      <td>Any failure to     establish  <font color="blue">relationships</font>  with  third  parties  for  our <font color="blue">manufacturing</font>     <font color="blue">requirements</font> <font color="blue">on <font color="blue">commercially</font></font> acceptable <font color="blue">terms would</font> have a material adverse     effect on us</td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent</font> in part on <font color="blue">third parties</font> for drug <font color="blue">development</font> and research     <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>We do not possess research and <font color="blue">development</font> <font color="blue">facilities</font> <font color="blue">necessary</font> to     conduct all of our drug <font color="blue">development</font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>We engage <font color="blue">consultants</font> and     in<font color="blue">dependent</font> contract research <font color="blue">organization</font>s to design and <font color="blue">conduct clinical</font>     trials in <font color="blue">connection with</font> the <font color="blue">development</font> of our drugs</td>
    </tr>
    <tr>
      <td>As a result, these     important  aspects  of a drug’s <font color="blue">development</font> will be outside our direct     control</td>
    </tr>
    <tr>
      <td>In addition, there can be no assurance that such <font color="blue">third parties</font> will     perform all of their obligations under <font color="blue">arrangements with</font> us or will perform     those <font color="blue">obligations satisfactorily</font></td>
    </tr>
    <tr>
      <td>In the future, we anticipate that we will need to obtain <font color="blue">additional</font> or     increased product <font color="blue">liability</font> insurance coverage and it is uncertain that such     increased or <font color="blue">additional</font> insurance coverage can be obtained <font color="blue">on <font color="blue">commercially</font></font>     reasonable terms</td>
    </tr>
    <tr>
      <td>Our business <font color="blue">will expose us</font> to potential product <font color="blue">liability</font> risks that     are inherent in the testing, <font color="blue">manufacturing</font> and marketing of <font color="blue">pharmaceutical</font>     products</td>
    </tr>
    <tr>
      <td>There can be no assurance that product <font color="blue">liability</font> claims will not     be asserted <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>We intend to obtain <font color="blue">additional</font> limited product     <font color="blue">liability</font>  insurance  for our <font color="blue"><font color="blue">clinical trial</font>s</font>, directly or through our     marketing  <font color="blue">development</font>  partners  or  contract  research  <font color="blue">organization</font>     (CRO) partners, when they begin in the US and to expand our insurance     coverage if and when we <font color="blue">begin marketing commercial products</font></td>
    </tr>
    <tr>
      <td>However, there     can  be  no assurance that we will be able to obtain product <font color="blue">liability</font>     insurance  <font color="blue">on <font color="blue">commercially</font></font> acceptable terms or that we will be able to     maintain <font color="blue">such insurance at</font> a <font color="blue">reasonable cost</font> or in <font color="blue">sufficient amounts</font> to     <font color="blue">protect against potential losses</font></td>
    </tr>
    <tr>
      <td>A successful product <font color="blue">liability</font> claim or     series of claims brought <font color="blue">against us</font> could have a material adverse effect on     us</td>
    </tr>
    <tr>
      <td>18       _________________________________________________________________    [78]Table of <font color="blue">Contents       </font>The <font color="blue">market price</font> of our shares, like that of many <font color="blue">bio<font color="blue">technology</font> companies</font>,     is <font color="blue">highly volatile</font></td>
    </tr>
    <tr>
      <td>Market prices for our <font color="blue">common stock</font> and the securities of other medical     and  biomedical <font color="blue">technology</font> companies have been <font color="blue">highly volatile</font> and may     continue to be <font color="blue">highly volatile</font> in the future</td>
    </tr>
    <tr>
      <td>Factors <font color="blue">such as announcements</font>     of <font color="blue">technological innovations</font> or <font color="blue">new products</font> by us or our <font color="blue">competitors</font>,     <font color="blue">government</font> <font color="blue">regulatory</font> action, <font color="blue">litigation</font>, patent or <font color="blue">proprietary rights</font>     <font color="blue">development</font>s, and <font color="blue">market conditions</font> for medical and high <font color="blue">technology</font> stocks     in general can have a <font color="blue">significant</font> impact on any <font color="blue">future market</font> for our common     stock</td>
    </tr>
    <tr>
      <td>If we <font color="blue">cannot satisfy</font> AMEX’s listing <font color="blue">requirements</font>, it may delist our common     stock and we may not have an <font color="blue">active public market</font> for our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>The     absence of an <font color="blue">active trading market would likely</font> make the <font color="blue">common stock</font> an     illiquid <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">common stock</font> is quoted on the <font color="blue">American Stock Exchange</font></td>
    </tr>
    <tr>
      <td>To continue     to be listed, we are required to maintain <font color="blue">shareholders equity</font> of dlra6cmam000cmam000     among  other  <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>We  do not satisfy that <font color="blue">requirement as</font> of     <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td><font color="blue">The AMEX </font>may consider delisting our <font color="blue">common stock</font> and     <font color="blue">suspend trading</font> in the <font color="blue">common stock</font> in which case our <font color="blue">common stock</font> would     <font color="blue">likely trade</font> in the over-the-counter market in the so-called “pink sheets”     or, if available, the “<font color="blue">OTC Bulletin Board Service</font></td>
    </tr>
    <tr>
      <td>” As a result, an investor     would likely find it <font color="blue"><font color="blue">significant</font>ly</font> more <font color="blue">difficult</font> to dispose of, or to     obtain accurate <font color="blue">quotations as</font> to the value of, our shares</td>
    </tr>
    <tr>
      <td>Our ability to     <font color="blue">raise capital would most likely also</font> be <font color="blue">impaired due</font> to our <font color="blue">ineligibility</font> to     <font color="blue">file resale registration statements under</font> the <font color="blue">Securities Act</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">common stock</font> is delisted, it may become subject to the SEC’s “penny     stock” rules and more <font color="blue">difficult</font> to sell</td>
    </tr>
    <tr>
      <td>SEC rules require brokers to provide information to purchasers of     securities traded at less than dlra5dtta00 and not traded on a <font color="blue">national securities</font>     exchange or quoted on the <font color="blue">Nasdaq Stock Market</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">common stock</font> becomes a     “<font color="blue">penny stock</font>” that is not <font color="blue">exempt from</font> these SEC rules, these <font color="blue">disclosure</font>     <font color="blue">requirements</font> may have the effect of <font color="blue">reducing trading activity</font> in our common     stock and making it more <font color="blue">difficult</font> for investors to sell</td>
    </tr>
    <tr>
      <td>The rules require     a broker-dealer to deliver a standardized risk <font color="blue">disclosure</font> document prepared     by the SEC that provides information about <font color="blue">penny stock</font>s and the nature and     level of risks in the <font color="blue">penny market</font></td>
    </tr>
    <tr>
      <td>The broker must also give bid and offer     quotations  and broker and <font color="blue">salesperson compensation</font> information to the     <font color="blue">customer orally</font> or in writing before or with the <font color="blue">confirmation</font></td>
    </tr>
    <tr>
      <td>The SEC rules     also require a broker to make a special written de<font color="blue">termination</font> that the penny     stock  is  a  suitable  <font color="blue">investment</font>  for  the purchaser and receive the     purchaser’s written <font color="blue">agreement</font> to the <font color="blue">transaction</font> before a <font color="blue">transaction</font> in a     <font color="blue">penny stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">Changes  </font>in  laws and <font color="blue">regulations</font> that affect the governance of public     companies has increased our operating expenses and will continue to do so</td>
    </tr>
    <tr>
      <td><font color="blue">Recently </font>enacted changes in the laws and <font color="blue">regulations</font> affecting public     companies, including the provisions of the Sarbanes-Oxley Act of 2002 and     the listing <font color="blue">requirements</font> for <font color="blue">American Stock Exchange</font> have <font color="blue">imposed new duties</font>     on  us  and  on  our  executives, directors, attorneys and in<font color="blue">dependent</font>     <font color="blue">accountants</font></td>
    </tr>
    <tr>
      <td>In order to <font color="blue">comply with</font> these new rules, we have hired and     expect  to hire <font color="blue">additional</font> personnel and use <font color="blue">additional</font> outside legal,     <font color="blue">accounting</font> and advisory services, which have increased and are likely to     <font color="blue">continue increasing</font> our operating expenses</td>
    </tr>
    <tr>
      <td>In particular, we expect to     incur <font color="blue">additional</font> <font color="blue">administrative</font> expenses as we implement Section 404 of the     Sarbanes-Oxley Act, which requires <font color="blue">management</font> to <font color="blue">extensively evaluate</font> and     report on, and our in<font color="blue">dependent</font> registered public <font color="blue">accounting</font> firm to attest     to,  our  <font color="blue"><font color="blue">internal control</font>s</font></td>
    </tr>
    <tr>
      <td>For example, we have incurred <font color="blue">significant</font>     expenses, and expect to incur <font color="blue">additional</font> expenses, in <font color="blue">connection with</font> the     evaluation, implementation, documentation and testing of our existing and     <font color="blue">newly implemented control systems</font></td>
    </tr>
    <tr>
      <td><font color="blue">Management </font>time <font color="blue">associated with</font> these     <font color="blue">compliance efforts necessarily reduces</font> time available for other operating     <font color="blue">activities</font>, which could <font color="blue">adversely</font> affect operating results</td>
    </tr>
    <tr>
      <td>If we are unable     to achieve full and timely compliance with these <font color="blue">regulatory</font> <font color="blue">requirements</font>, we     could be required to incur <font color="blue">additional</font> costs, expend <font color="blue">additional</font> money and     <font color="blue">management</font> time on <font color="blue">additional</font> remedial efforts which could <font color="blue">adversely</font> affect     our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Failure to implement <font color="blue">effective</font> control systems, or failure to complete our     <font color="blue">assessment</font> of the <font color="blue">effective</font>ness of our <font color="blue">internal control</font> <font color="blue">over financial</font>     reporting, may subject us to <font color="blue">regulatory</font> sanctions and could result in a loss     of public confidence, which could harm our operating results</td>
    </tr>
    <tr>
      <td><font color="blue">Pursuant to Section </font>404 of the Sarbanes-Oxley Act, <font color="blue">beginning with</font> our     <font color="blue">fiscal year</font> ending <font color="blue">December </font>31, 2005, we are required to include in our     annual report our <font color="blue">assessment</font> of the <font color="blue">effective</font>ness of our <font color="blue">internal control</font>     <font color="blue">over financial</font> reporting</td>
    </tr>
    <tr>
      <td>Furthermore, our in<font color="blue">dependent</font> registered public     <font color="blue">accounting</font> firm is required to issue an <font color="blue">opinion on whether</font> our <font color="blue">assessment</font> of     the <font color="blue">effective</font>ness of our <font color="blue">internal control</font> <font color="blue">over financial</font> reporting is fairly     stated in all material respects and <font color="blue">separately</font> report on whether it believes     we maintained, in all material respects, <font color="blue">effective</font> <font color="blue">internal control</font> over     financial reporting as of <font color="blue">December </font>31, 2005</td>
    </tr>
  </tbody>
</table>